Dr. Phil Wolfson, MD, is the Founder and CEO of the Ketamine Research Foundation, which advances ketamine’s use in therapeutic modalities. As a pioneering psychiatrist and psychotherapist, he is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. Dr. Wolfson served as the Principal Investigator for a MAPS-sponsored Phase 2 clinical trial exploring MDMA-assisted psychotherapy for patients with anxiety from life-threatening illnesses. 

In this episode…

As psychedelic-assisted therapies become more mainstream, ketamine treatments are increasingly medicalized, often lacking the integration, connection, and context that can unlock their true healing potential. How can clinicians ensure these therapies are transformative rather than transactional?

Psychedelic psychotherapist Dr. Phil Wolfson advises against separating ketamine from psychotherapy. Instead, he advocates for an integrative, human-centered approach that includes preparatory work, therapist presence, and post-session integration. When determining patient dosage, clinicians should focus on assessing the individual rather than adhering to rigid protocols. Dr. Wolfson also urges clinicians to cultivate compassion, deepen their therapeutic relationships, and consider the spiritual and emotional dimensions of healing, especially when working with trauma and grief. 

In this episode of Living Medicine, Dr. Sandy Newes talks with Dr. Phil Wolfson, the Founder and CEO of the Ketamine Research Foundation, about the art and ethics of ketamine-assisted psychotherapy. Dr. Wolfson shares how his son’s illness led him to pursue psychedelic-assisted psychotherapy, consciousness and death in psychedelic experiences, and the contrast between IV clinics and integrative therapy models.